If it’s shown to be safe and effective for treating Covid-19, the medication is estimated to cost about $9 a treatment to make, said Andrew Hill, a senior visiting research fellow in the pharmacology department at Liverpool University, and colleagues in a study Friday.
As an intravenous infusion, there would be additional costs to administer remdesivir, which are likely to exceed the estimated manufacturing, the authors said.
Results of controlled studies of remdesivir are highly anticipated because they will be some of the first rigorous large-scale studies completed on potential anti-coronavirus drugs.
President Donald Trump and others have touted the potential of hydroxychloroquine, an old malaria and lupus drug, for treating Covid-19. But that drug hasn’t yet been carefully studied in a large trial to see if it prevents severe complications. Most of the excitement stems from relentless social media promotion of a tiny French study whose methodology has been heavily criticized by many U.S. medical experts.
Remdesivir, a broad-spectrum antiviral, is viewed by researchers and doctors as one of the most promising agents against Covid-19 to enter human trials to date. In lab studies conducted prior to the Covid-19 outbreak on numerous compounds, researchers at the University of North Carolina and Vanderbilt University found the drug had potent activity against against a wide variety of coronaviruses similar to the new coronavirus.